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Surveillance of Viral Hepatitis – United States, 2014 
SUMMARY 
As part of the Centers for Disease Control and Prevention’s (CDC) National Notifiable Diseases 
Surveillance System (NNDSS) (1), viral hepatitis case-reports are received electronically from 
U.S. state and territorial health departments via CDC’s National Electronic Telecommunications 
System for Surveillance (NETSS), a computerized public health surveillance system that 
provides CDC with data on a weekly basis. Although the surveillance infrastructure was in place 
for states to report both acute and chronic infections, case-reports of chronic hepatitis B virus 
(HBV) and past or present hepatitis C virus (HCV) infections, which account for the greatest 
burden of disease, were not submitted by all states; in 2014, 40 states submitted reports of 
chronic HBV infection and 37 states submitted reports of chronic HCV infection.  
The NNDSS data in this report should be interpreted with the understanding that “reported 
cases” of viral hepatitis represent persons who were tested for and diagnosed with viral hepatitis 
infection based on a relatively stringent case definition. Because most infections with viral 
hepatitis are asymptomatic, all cases are not identified or reported. As a result, this Summary is 
most useful in detecting trends over time for newly reported cases of hepatitis A virus (HAV), 
HBV, and HCV infections. However, to account for  under-ascertainment and under-reporting, 
an estimation method was developed in 2011 to better quantify the number of new cases of 
hepatitis A, B, and C from the actual number of cases reported for each disease (2). The 
estimates in this report were derived from this methodology. We therefore caution the reader that 
estimates before 2011, which were obtained using a different, unpublished methodology, cannot 
be compared with those from 2011 to the present.  
With progressive infant hepatitis A vaccination recommendations since 1996 and universal 
infant vaccination since 2006, vaccination rates and evidence of vaccine-induced immunity in 
young persons have increased in the past decade (3,4). Despite protection among young persons, 
many older adults have not been vaccinated and are therefore susceptible to infection. From 2011 
to 2013, an increase in the number of reported cases of hepatitis A was observed. However in 
2014, a total of 1,239 cases of hepatitis A were reported, representing a 30.4% decrease from 
2013. This decline was the result of a large 2013 hepatitis A outbreak among persons who 
consumed imported pomegranate seeds in several southwestern states and Hawaii (5). After 
adjusting for under-ascertainment and under-reporting (2), the estimated number of new HAV 
infections in 2014 was 2,500. 
Acute hepatitis B has been declining in incidence since 1990 mainly due to effective vaccination 
strategies. The number of reported cases of acute hepatitis B has remained relatively stable since 
2009. A total of 2,791 acute cases were reported in 2014. However, chronic HBV infection
remains a major public health challenge; recent CDC investigations report approximately 
850,000 HBV-infected persons in the United States (6, 7), although other studies have estimated 
that as many as 2.2 million persons are living with HBV infection (8). Surveillance data from 
enhanced surveillance sites in this report indicate about one-half of chronic HBV infections were 
among Asians/Pacific Islanders, and 71.3% of chronic HBV infections were among persons born 
Surveillance for Viral Hepatitis — United States, 2014 
4 
outside of the United States. Other data indicate that approximately 47%–70% of persons with 
HBV infection living in the United States were born in other countries (9). Among foreign-born 
persons with chronic HBV infection, an estimated 58% migrated from Asia (8). Further, 
mortality data in this report show that disproportionate numbers of Asians/Pacific Islanders are 
dying with hepatitis B. Identifying these chronically infected persons and linking them to care is 
critical (10, 11). The U.S. Preventive Services Task Force (USPSTF) joined with CDC in 2014 
to  recommend HBV testing for persons born in countries where HBV infection is endemic (12). 
After adjusting for under-ascertainment and under-reporting (2), the estimated number of new 
HBV infections in 2014 was 18,100.
After receiving reports of cases of acute hepatitis C ranging from 781-877 during the years 
2006–2010, reported cases of acute HCV infection increased more than 2.5 times from 2010–
2014. Cases of acute HCV infection rose annually, from 850 in 2010 to 1,232 in 2011, 1,778 in 
2012, 2,138 in 2013, and 2,194 in 2014. The increase from 2010–2014 is thought to reflect both 
true increases in incidence and, to a lesser extent, improved case ascertainment. Based on new 
epidemiologic studies, at least 4.6 million persons are HCV-antibody positive and approximately 
3.5 million are currently infected with HCV (13). New cases of HCV infection are predominately 
among young persons who are white, live in non-urban areas (particularly in Eastern and 
Midwestern states), have a history of injection-drug use, and previously used opioid agonists 
such as oxycodone (14). Improved case ascertainment by Florida, Massachusetts, and New York, 
which were funded by CDC to conduct enhanced surveillance, partially explains the increased 
incidence of acute HCV infection in these states. In other locations where the number of cases 
has increased markedly (e.g., Kentucky, Tennessee, Virginia, and West Virginia), increases have 
occurred without any federal support for investigation or follow-up, reflecting overall increases 
in incidence (15, 16). After adjusting for under-ascertainment and under-reporting (2), an 
estimated 30,500 new HCV infections occurred in 2014.
Mortality among HCV-infected persons—primarily adults aged 55–64 years—is increasing (17, 
18). For the first time in the United States (17), in 2007 the number of HCV-related deaths 
(n=15,106) exceeded the number of HIV/AIDS-related deaths (n=12,734) (17) and has since 
continued to increase. The number of HCV-related deaths rose to 19,659 in 2014 and more than 
one-half of deaths occurred among persons aged 55-64 years. A key public health challenge is to 
increase the proportion of persons tested, and of those who are currently infected, increase the 
proportion referred for care and treatment (10, 11). To address this challenge the USPSTF joined 
with CDC in 2013 to recommend one-time testing for HCV infection among adults born during 
1945–1965 (19). 
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BACKGROUND 
Viral hepatitis is caused by infection with any of at least five distinct viruses: hepatitis A virus 
(HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), and hepatitis 
E virus (HEV). Most viral hepatitis infections in the United States are attributable to HAV, HBV, 
and HCV. All three of these unrelated viruses can produce an acute illness characterized by 
nausea, malaise, abdominal pain and jaundice, although many of these acute infections are 
asymptomatic or cause only mild disease. Thus, many persons infected with HBV or HCV are 
unaware they are infected and have clinically silent infections for decades until developing 
cirrhosis, end-stage liver disease, or hepatocellular carcinoma. 
Hepatitis A 
Transmitted through the fecal-oral route, HAV is acquired primarily through close personal 
contact with an infected person and during foodborne outbreaks (20). Unlike hepatitis B and C, 
hepatitis A does not cause chronic infection. Since 1995, effective vaccines to prevent HAV 
infection have been available in the United States, increasing feasibility of eliminating 
indigenous transmission. In 1996, CDC’s Advisory Committee on Immunization Practices 
(ACIP) recommended administration of hepatitis A vaccine to persons at increased risk for the 
disease, including international travelers, men who have sex with men (MSM), persons who use 
drugs and persons who inject drugs (PWID), and children living in communities with high rates 
of disease (21). In 1999, ACIP expanded these recommendations to include children living in 11 
states with average hepatitis A rates of >20 cases per 100,000 population and recommended that 
vaccination be considered for children in an additional six states with rates of 10–20 cases per 
100,000 population (22). In 2006, ACIP expanded these recommendations to include routine 
vaccination of children aged >1 year in all 50 states (4). 
Hepatitis B 
HBV is transmitted by percutaneous or mucosal exposure to blood or body fluids of an infected 
person, such as from an infected mother to her newborn during childbirth, through close personal 
contact within households, through unscreened blood transfusion or unsafe injections in health-
care settings, through injection drug use, and from sexual contact with an infected person. Adults 
with diabetes mellitus are at an increased risk of acquiring HBV infection if they share diabetes-
care equipment such as blood glucose meters, finger stick devices, syringes and/or insulin pens. 
Adults with diabetes aged <60 years are thus recommended to receive hepatitis B vaccination 
and those aged >60 years are to be considered for vaccination (23). 
Risk for chronic HBV infection decreases with increasing age at infection. Of infants who 
acquired HBV infection from their mothers at birth, as many as 90% become chronically 
infected, whereas 30%–50% of children infected at age 1–5 years become chronically infected. 
This percentage is smaller among adults, for whom approximately 5% of all acute HBV 
infections progress to chronic infection (24, 25). 
Effective vaccines to prevent HBV infection have been available in the United States since 1981. 
Ten years later, a comprehensive strategy was recommended for the elimination of HBV 
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transmission in the United States (26, 27); the strategy was revised to include catch-up 
vaccination of older children, adolescents and other populations. The current vaccine-based 
strategy for the elimination of HBV transmission encompasses the following four components: 
 Universal vaccination of infants beginning at birth;
 Prevention of perinatal HBV infection through routine screening of all pregnant women
for HBV infection and provision of hepatitis B vaccine and immunoprophylaxis to infants
born to hepatitis B surface antigen (HBsAg)-positive mothers;
 Routine vaccination of previously unvaccinated children and adolescents; and
 Vaccination of adults at increased risk for infection (including health-care workers,
dialysis patients, adults with diabetes, household contacts and sex partners of persons
with chronic HBV infection, recipients of certain blood products, persons with a recent
history of having multiple sex partners concurrently, those infected with a sexually
transmitted disease, MSM, and PWID).
In addition to hepatitis B vaccination, efforts have been made to improve care and treatment for 
persons who are living with hepatitis B. In the United States, 850,000–2.2 million persons are 
estimated to be living  with HBV infection (7,8), many of whom are unaware of their infection 
status (10). To improve health outcomes for these persons, in 2008 CDC recommended HBV 
testing for populations at risk for HBV infection and public health management of persons living 
with chronic HBV infection (9). These guidelines stress the need for testing persons at high risk 
for infection, conducting contact management, educating patients, and administering FDA-
approved therapies for treating hepatitis B. Other recent guidelines address the appropriate 
management of chronic HBV infection among surgeons, other health-care workers, and students 
(29). 
Hepatitis C 
HCV is transmitted primarily through percutaneous (parenteral) exposure that can result from 
injection-drug use, needle stick injuries, and inadequate infection control in health-care settings. 
Much less often, HCV transmission occurs among HIV-positive persons, especially MSM, as a 
result of sexual contact with an HCV-infected partner (30, 31), among persons who receive 
tattoos in unregulated settings (31), and among infants born to HCV-infected mothers (32). After 
adjustment for populations not sampled in the NHANES household surveys, such as incarcerated 
and homeless populations, an estimated 3.5 million persons are living with HCV infection in the 
United States (28). 
A single positive anti-HCV result cannot distinguish between acute and chronic HCV infection 
or between current or resolved (cleared) HCV infection. Approximately 75%–85% of newly 
infected adults and adolescents develop chronic HCV infection (33). A revised CDC algorithm 
for HCV testing includes anti-HCV testing and if positive, a nucleic acid test (NAT) to detect 
current HCV infection (34). For reporting purposes, making the distinction between an acute and 
chronic HCV infection requires a health department to have data to detect the conversion from 
anti-HCV negative to anti-HCV positive or follow-up with a provider to determine if there were 
symptoms or signs of liver disease meeting the criteria for acute HCV infection. Laboratory 
criteria in the 2012 definition for cases of “past or present” HCV infection require one or more of 
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the following: anti-HCV positive (repeatedly reactive) by EIA, verified by at least one more 
specific assay, or HCV RIBA positive, or HCV NAT positive, or anti-HCV screening-test 
positive with an assay-specific signal-to-cutoff ratio predictive of a true case. This assessment 
requires, on average, review of at least four records by hepatitis surveillance staff in health 
departments (35). No clinical symptoms are required; however, the case must be known to not be 
acute. It should also be noted that in 2013, the RIBA test was phased out in the United States.  
National recommendations (36) for preventing HCV infection include screening and testing 
donors of blood, other tissues and organs, inactivating HCV in plasma-derived products, testing 
persons at risk for HCV infection and providing risk-reduction counseling and recommended 
care and treatment, access to safe injection equipment for persons who inject drugs, and 
consistently implementing and practicing infection control in health-care settings. In 2010, FDA 
approved point-of-care tests for HCV infection that yield prompt results available to patients 
during the same clinical visit (37). In 2012, CDC augmented existing recommendations for HCV 
screening based on risk to include recommendations for one-time screening for HCV infection 
among all those born during 1945–1965 (38). It is estimated that persons born during these years 
have a 3% prevalence of HCV antibodies, which is six times higher than the prevalence seen in 
adults born in other years (38). Of all persons living with HCV infection, about 75% were born 
during 1945–1965; a similar percentage of HCV-associated deaths can be attributed to this birth 
cohort (39). The goal of birth-cohort HCV testing is to identify unrecognized infections among 
the segment of the population at highest risk for HCV-associated morbidity and mortality, 
thereby increasing opportunities for persons infected with HCV to benefit from appropriate care 
and treatment. 
Linkage to care and treatment is critical to improving health outcomes for persons found to be 
infected with HCV. Such linkage is particularly important in light of major advancements that 
have been made in HCV treatments. For patients infected with HCV, treatment previously 
consisted of pegylated interferon (PEG_INF) combined with oral doses of ribavirin (40). 
Approximately 40%-50% of HCV-infected patients receiving this therapy cleared their infection 
(40). However, HCV treatment improved drastically in 2011 with development of the initial 
direct-acting oral agents, telaprevir and boceprevir, which were capable of achieving a sustained 
virologic response (SVR) rate of >80% (40, 41). These two drugs were available during the 
reporting period in 2013 covered by this Surveillance Report, but they are now discontinued in 
the United States and replaced with newer, all-oral direct-acting antiviral agents. In 2013, FDA 
approved use of simeprevir and sofosbuvir (42). When given in combination with PEG-INF and 
ribavirin or as an all-oral combination regimen for a shorter duration of 8-12 weeks, these agents 
increase SVR rates to >90% (43, 44). In 2014, two all-oral regimens, Harvoni 
(ledipasvir/sofosbuvir) and Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir 
tablets), were licensed for the treatment of HCV, and newer all oral agents are being continually 
added, such as ZEPATIER (elbasvir and grazoprevir) in 2016. These direct-acting, short-course 
(8 to12 week for most patients), all-oral, largely (>90%) curative agents are now the standard-of-
care for HCV treatment in the United States. Evidence-based guidance is available from 
AASLD/IDSA to assist providers caring for HCV-infected patients (45). The AASLD/IDSA 
HCV guidance is continuously updated to incorporate new information regarding HCV testing, 
linkage to care, and treatment (http://www.hcvguidelines.org).  
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Sources of Information 
CDC relies on several sources of information to determine the incidence, prevalence, trends, and 
burden of hepatitis A, B, and C disease.  
National Notifiable Diseases Surveillance System (NNDSS) 
Background 
The basis for most case-reports is passive surveillance through the National Notifiable Diseases 
Surveillance System (NNDSS). State and local health departments report acute hepatitis A, B and 
C (incident cases) through this system. However, a number of states do not report cases of 
chronic hepatitis B and C through the NNDSS. Collecting, verifying, and reporting the many 
cases of hepatitis B and C in the United States (estimated at over 4 million) are beyond the 
capability of many health departments. Reports of chronic hepatitis B and C are included in this 
Surveillance Summary from states that gave CDC permission to publish those counts.  
Each week, state and territorial health departments report cases of acute, symptomatic viral 
hepatitis to CDC’s NNDSS. Since 1990, states have been electronically submitting individual 
case-reports (absent of personal identifiers) to CDC. States’ participation in notifying CDC of 
cases of nationally notifiable diseases, including viral hepatitis, is voluntary.  
National surveillance for viral hepatitis (including acute hepatitis A, hepatitis B, and hepatitis C; 
chronic hepatitis B; and past or present hepatitis C) is based on case definitions developed and 
approved by the Council of State and Territorial Epidemiologists (CSTE) and CDC. Reported 
cases of acute and chronic viral hepatitis are required to meet the following clinical and 
laboratory criteria (available at: https://wwwn.cdc.gov/nndss/conditions/notifiable/2014/.  
However, these criteria are evaluated at state or local health departments and are not validated by 
CDC. Although states may classify cases as confirmed, probable, and suspect, only confirmed
cases of acute viral hepatitis are presented in this report. Updated CSTE Case definitions are
available at the CSTE website: https://wwwn.cdc.gov/nndss/case-definitions.html.
Adjustments to Reported Cases from the National Notifiable Diseases Surveillance System 
To better estimate the incidence of acute hepatitis A, B, and C in the United States, CDC 
developed a model to account for under-ascertainment and under-reporting of cases of hepatitis 
A, B, and C. The model factored in the probabilities of an infected person developing symptoms 
such as jaundice (I), referral to care and treatment (II), and rates of reporting to local and state 
health departments (III). Results of the analysis estimated that reported cases represent 1 of every 
2 hepatitis A cases, 1 of every 6.5 acute hepatitis B cases, and 1 of every 13.9 acute hepatitis C 
cases (2). Accordingly, to obtain the estimated number of acute hepatitis A, B, and C after 
accounting for under-ascertainment and under-reporting, these new estimators were first applied 
to the acute hepatitis case data from NNDSS in the 2011 Surveillance Summary and will 
continue to be applied to future annual surveillance summaries, including this report. These 
estimates cannot be used to deduce trends by comparison with estimations obtained in years prior 
to 2011, as earlier estimates were based on different (and unpublished) calculations; still, trends 
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in reported cases can be evaluated, for example, the trend in the increase in acute hepatitis C that 
was first observed in 2011 among nationally reported cases. 
Enhanced Viral Hepatitis Surveillance Sites 
Background 
In November 2012, CDC funded seven health departments to conduct enhanced viral hepatitis 
surveillance through a 3-year, extended to 4 years, CDC funding agreement. All chronic cases of 
viral hepatitis obtained through these sites are de-duplicated. Additionally, for a sample of cases 
(and all cases in some sites such as New York State), follow-up case investigation is conducted 
by health departments to obtain clinical, laboratory, and epidemiologic information, including 
risk exposures and behaviors. Each quarter, a dataset of cumulative cases from each site was sent 
to CDC through the CDC Secure Access Management System (SAMS), a secure electronic file 
transfer portal.  
Methods 
CDC funded five states (Florida, Massachusetts, Michigan, New York, and Washington) and two 
cities (Philadelphia and San Francisco) to conduct “enhanced,” or “active” viral hepatitis 
surveillance, representing a combined population of approximately 55.7 million persons. In each 
of these jurisdictions, clinical laboratories were mandated to submit laboratory reports from 
persons with positive HBV and HCV test results to state or local health departments. 
Participating health departments routinely review each report to assess whether current case 
definitions were met as established by CSTE and CDC. To determine whether a case is new, 
each site matches new case-reports to existing cases in the surveillance registry using personal 
identifying information. New cases are added to an electronic registry, whereas duplicate cases 
are used to update previous reports. Most health departments collect basic demographic data 
(e.g., age and sex) from the laboratory reports. Efforts vary by site regarding the level of 
investigation undertaken to collect and store supplemental information (e.g., risk factor data) 
from patients or their providers. 
Data analyses from participating enhanced surveillance sites presented in this surveillance report 
were conducted on all serologically confirmed cases of chronic hepatitis B and chronic (past or 
present) hepatitis C infection reported for the year 2014. Rates were calculated using appropriate 
jurisdiction-specific (state, county, or city) 2014 population estimates obtained from the U.S. 
Census Bureau. 
Limitations 
The number of cases of chronic HBV infection and past or present HCV infection from 
participating enhanced surveillance sites included in this report is likely an underestimate of the 
true burden of disease because cases of chronic infection are generally asymptomatic and less 
likely to be identified and reported. Additionally, data from these sites are not representative of 
the U.S. population, and because not all sites conduct comprehensive follow-up, data regarding 
race/ethnicity, place of birth, and risk exposures and behaviors are missing for some case-reports. 
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Mortality/Death Certificates 
Background 
Death certificates are completed for all deaths registered in the United States. Information from 
death certificates is provided by funeral directors, attending physicians, medical examiners, and 
coroners, and certificates are filed in vital statistics offices within each state and the District of 
Columbia. Through a program called the National Vital Statistics System (NVSS) (46), 
information from death certificates is compiled by CDC’s National Center for Health Statistics 
(NCHS) to produce national multiple-cause-of-death (MCOD) data (45); causes of death are 
coded in accordance with the International Classification of Diseases, Tenth Revision (ICD-10) 
(47). MCOD data are used to determine the national burden of mortality associated with viral 
hepatitis and to characterize decedents. 
A major study of these records from 1999–2007 showed that in 2007, the annual number of 
deaths associated with  HCV-infection exceeded the annual number of deaths associated with 
HIV infection (17). A more recent study using death certificate data from 2003-2013 showed that 
the number of deaths associated with HCV infection continued to increase since 2007, and in 
2012, surpassed the combined number of deaths associated with 60 other nationally notifiable 
infectious conditions that are routinely reported to CDC (48).  The HCV mortality burden is 
likely much greater than these numbers suggest because death certificate validation studies have 
concluded that only a fraction of HCV-infected decedents have HCV listed on their death 
certificate, even when pre-mortem evidence of serious liver disease is present (18). 
Methods 
We obtained and analyzed 2010–2014 national multiple-cause mortality data through NVSS. The 
following case definitions were used to identify a death associated with hepatitis A, B, and C. 
Any death record with a report of any of the following ICD-10 codes listed as the underlying or 
one of the multiple (e.g., contributing) causes of death in the record axis: 
 Hepatitis A (ICD-10: B15), 
 Hepatitis B (ICD-10: B16, B17.0, B18.0, and B18.1), or 
 Hepatitis C (ICD-10: B17.1 and B18.2). 
Demographic information on age, race/ethnicity, and sex were examined. Deaths were divided 
into six age categories: 0–34, 35–44, 45–54, 55–64, 65–74, and >75 years. Race was divided into 
the following categories: white, non-Hispanic; black, non-Hispanic; Hispanic; Asian/Pacific 
Islander (API); and American Indian/Alaska Native (AI/AN). To calculate national mortality 
rates, the number of deaths associated with each type of hepatitis was divided by the total U.S. 
Census population for each demographic characteristic. Rates on race/ethnicity, sex, and overall 
total were standardized to the age distribution of the U.S. standard population in 2000 (49).  
 
 
Interpretation of Mortality Data (Limitations) 
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 Differences in recording practices of death certificate information may cause
misclassification of ICD-10 codes and demographic information.
 Certain racial/ethnic populations likely are underrepresented in US Census data (the
denominator for calculating rates), potentially causing overestimated rates for these
populations.
 HBV and HCV infections are often underreported as causes of death on death certificates.
These analyses do not adjust for deaths resulting from undiagnosed viral hepatitis
infections.
 Death records listing more than one type of viral hepatitis infection were counted once
for each type of infection. For example, a death with ICD-10 codes for both hepatitis B
and C virus infections is counted once as a hepatitis B death and once as a hepatitis C
death.
 Before 2010, the race category designated as “non-white/non-black” included all other
racial groups (e.g., APIs, AI/ANs, and persons who are Hispanic). This lack of specificity
limits race-specific interpretation of mortality data prior to 2010.
Investigation of Healthcare-Associated Outbreak Cases 
In 2014, CDC participated in two state-based investigations of healthcare-associated outbreaks of 
HBV infection and four state-based investigations of healthcare-associated outbreaks of HCV 
infection.  Additional information may be found at the following link that summarizes known 
outbreaks that occurred during 2008–2014 (available at: 
http://www.cdc.gov/hepatitis/statistics/healthcareoutbreaktable.htm). 
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HEPATITIS A 
Hepatitis A  
Hepatitis A rates vary cyclically, with nationwide increases every 10–15 years. The last peak was 
in 1995; since that time, rates of hepatitis A generally declined until 2011. In 2014, a total of 
1,239 cases of hepatitis A were reported from 50 states to CDC (Table 2.1), a 30.4% decrease 
from 2013. This decrease reflects cases identified during a large hepatitis A outbreak from 
imported pomegranate seeds consumed by persons in several southwestern states and Hawaii in 
2013 (6). The overall incidence rate in 2014 was 0.4 cases per 100,000 population. After 
adjusting for under-ascertainment and under-reporting, an estimated 2,500 hepatitis A cases 
occurred in 2014. (Data for 2014 were unavailable for the District of Columbia.) 
 
2012 CSTE/CDC Case Definition (NNDSS) 
Clinical Description 
Acute hepatitis is defined as acute illness with 1) discrete onset of symptoms (e.g., fever, 
headache, malaise, anorexia, nausea, vomiting, diarrhea, and abdominal pain) and 2) jaundice, 
or elevated serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels. 
Laboratory Criteria  
Immunoglobulin M (IgM) antibody to hepatitis A virus (anti-HAV) positive. 
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Table 2.1. Reported cases of hepatitis A, nationally and by state or jurisdiction ― United 
States, 2010–2014 
State 
2010 2011 2012 2013 2014 
No. Rate* No. Rate* No. Rate* No. Rate* No. Rate* 
Alabama 8 0.2 8 0.2 19 0.4 10 0.2 15 0.3 
Alaska 5 0.7 4 0.6 1 0.1 1 0.1 1 0.1 
Arizona 61 1.0 77 1.2 93 1.4 66 1.0 29 0.4 
Arkansas 2 0.1 3 0.1 8 0.3 9 0.3 2 0.1 
California 242 0.6 186 0.5 209 0.5 255 0.7 142 0.4 
Colorado 36 0.7 21 0.4 28 0.5 51 1.0 23 0.4 
Connecticut 29 0.8 18 0.5 23 0.6 19 0.5 23 0.6 
Delaware 7 0.8 2 0.2 9 1.0 4 0.4 1 0.1 
District of 
Columbia 1 0.2 U U U U U U U U 
Florida 139 0.7 87 0.5 87 0.5 115 0.6 90 0.5 
Georgia 40 0.4 27 0.3 46 0.5 36 0.4 24 0.2 
Hawaii 8 0.6 8 0.6 5 0.4 16 1.1 5 0.4 
Idaho 8 0.5 6 0.4 11 0.7 8 0.5 7 0.4 
Illinois 48 0.4 73 0.6 67 0.5 79 0.6 82 0.6 
Indiana 12 0.2 24 0.4 11 0.2 32 0.5 20 0.3 
Iowa 11 0.4 8 0.3 7 0.2 17 0.6 12 0.4 
Kansas 14 0.5 4 0.1 15 0.5 11 0.4 7 0.2 
Kentucky 26 0.6 10 0.2 25 0.6 24 0.5 19 0.4 
Louisiana 11 0.2 5 0.1 7 0.2 14 0.3 5 0.1 
Maine 7 0.5 6 0.5 9 0.7 10 0.8 8 0.6 
Maryland 23 0.4 26 0.4 28 0.5 29 0.5 27 0.5 
Massachusetts 48 0.7 39 0.6 40 0.6 43 0.6 43 0.6 
Michigan 73 0.7 70 0.7 100 1.0 83 0.8 45 0.5 
Minnesota 37 0.7 27 0.5 29 0.5 32 0.6 19 0.3 
Mississippi 2 0.1 7 0.2 11 0.4 5 0.2 3 0.1 
Missouri 21 0.4 13 0.2 20 0.3 8 0.1 20 0.3 
Montana 4 0.4 3 0.3 6 0.6 6 0.6 5 0.5 
Nebraska 14 0.8 5 0.3 16 0.9 13 0.7 9 0.5 
Nevada 14 0.5 5 0.2 10 0.4 19 0.7 5 0.2 
New 
Hampshire 2 0.2 0 0 6 0.5 9 0.7 5 0.4 
New Jersey 76 0.9 79 0.9 60 0.7 68 0.8 59 0.7 
New Mexico 5 0.2 7 0.3 10 0.5 20 1.0 8 0.4 
New York 147 0.8 113 0.6 111 0.6 167 0.8 84 0.4 
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North 
Carolina 48 0.5 31 0.3 34 0.3 46 0.5 38 0.4 
North Dakota 4 0.6 0 0 2 0.3 9 1.2 9 1.2 
Ohio 47 0.4 39 0.3 36 0.3 59 0.5 32 0.3 
Oklahoma 6 0.2 11 0.3 12 0.3 14 0.4 17 0.4 
Oregon 17 0.4 11 0.3 9 0.2 29 0.7 13 0.3 
Pennsylvania 53 0.4 60 0.5 62 0.5 53 0.4 48 0.4 
Rhode Island 9 0.9 8 0.8 3 0.3 4 0.4 8 0.8 
South 
Carolina 26 0.6 11 0.2 6 0.1 14 0.3 6 0.1 
South Dakota 1 0.1 2 0.2 0 0 4 0.5 3 0.4 
Tennessee 12 0.2 23 0.4 23 0.4 20 0.3 12 0.2 
Texas 139 0.6 138 0.5 134 0.5 109 0.4 124 0.5 
Utah 12 0.4 8 0.3 4 0.1 12 0.4 8 0.3 
Vermont 0 0 6 1.0 2 0.3 7 1.1 1 0.2 
Virginia 52 0.6 30 0.4 49 0.6 36 0.4 27 0.3 
Washington 21 0.3 31 0.5 29 0.4 45 0.6 26 0.4 
West Virginia 15 0.8 8 0.4 8 0.4 4 0.2 12 0.6 
Wisconsin 23 0.4 8 0.1 21 0.4 37 0.6 7 0.1 
Wyoming 4 0.7 2 0.4 1 0.2 0 0 1 0.2 
U.S. 1670 0.5 1398 0.4 1562 0.5 1781 0.6 1239 0.4 
*Rate per 100,000 population.  
U=No data available for reporting. 
Source: CDC, National Notifiable Diseases Surveillance System. 
 
 The number of hepatitis A cases reported in the United States has declined, from 1,670 
reported cases in 2010 to 1,239 reported cases in 2014.  
 Of the 50 states that reported hepatitis A cases in 2014, a total of 21 had rates below the 
national rate.  
 In 2014, the case rate ranged from 0.1 cases per 100,000 in seven states to 1.2 cases per 
100,000 population in North Dakota.  
 There are 21 states (42%) that met  the Healthy People 2020 goal 
(https://www.healthypeople.gov/) of reducing hepatitis A incidence to <0.3 cases/100,000 
population : Alabama, Alaska, Arkansas, Delaware, Georgia, Indiana,  Kansas, 
Louisiana, Minnesota, Mississippi, Missouri, Nevada, Ohio, Oregon, South Carolina, 
Tennessee, Utah, Vermont, Virginia, Wisconsin, and Wyoming.  
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Table 2.2. Clinical characteristics of reported cases of hepatitis A* ― United States, 2014 
Clinical characteristic 
Availability of valid 
data† for clinical 
characteristic 
Cases with clinical 
characteristic§  
No. % No. % 
Jaundice 757 61.1 456 60.2 
Hospitalized for hepatitis A 757 61.1 344 45.4 
Died from hepatitis A 671 54.2 0 0 
*A total of 1,239 hepatitis A cases were reported during 2014.
†Case-reports for which questions regarding clinical characteristics were answered with “yes” or “no.” Reports with
any other response were excluded.
§Numbers and percentages represent only those case-reports for which data regarding clinical characteristics were
available; numbers likely are underestimates.
Source: CDC, National Notifiable Diseases Surveillance System.
 Of the 1,239 case-reports of hepatitis A received during 2014, 61.1% included
information about whether the patient had jaundice, 61.1% included information
regarding hospitalization caused by hepatitis A, and 54.2% included information on death
from hepatitis A.
 Jaundice was reported for 456 (60.2%) of the 757 hepatitis A case-reports that included
information about jaundice.
 Hospitalization as the result of hepatitis A was reported for 344 (45.4 %) of the 757
hepatitis A case-reports that included information about hospitalization.
 There were no deaths reported for hepatitis A.
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Figure 2.1. Reported number of hepatitis A cases — United States, 2000-2014 
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Source: CDC, National Notifiable Diseases Surveillance System. 
 
• The number of hepatitis A cases declined by 90.8%, from 13,397 in 2000 to 1,239 in 
2014. 
• From 2010 through 2014, the number of hepatitis A cases decreased by 25.8% (from 
1,670 to 1,239); this number decreased 20.7% over the years 2012–2014, from 1,562 to 
1,239.  
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Figure 2.2. Incidence of hepatitis A, by age group — United States, 2000–2014 
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Source: CDC, National Notifiable Diseases Surveillance System. 
• From 2000–2014, rates of hepatitis A declined, except for an increase in 2012 and 2013
among all age groups excluding those aged 0–9 and 10–19 years.
• When comparing the 2014 hepatitis A rates of all age groups, persons aged 20–29 years
had the highest rate (0.55 cases per 100,000 population); persons aged 0–9 years had the
lowest rate (0.10 cases per 100,000 population).
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Figure 2.3. Incidence of hepatitis A, by sex — United States, 2000–2014 
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Source: CDC, National Notifiable Diseases Surveillance System. 
 From 2000–2011, rates of hepatitis A among males and females both declined, and by
2011, the rates in these two groups were similar.
 In 2014, the incidence rate was 0.4 cases per 100,000 population for males and females.
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Figure 2.4. Incidence of hepatitis A, by race/ethnicity — United States, 2000–2014 
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Source: CDC, National Notifiable Diseases Surveillance System. 
• From 2000–2007, rates of hepatitis A among Hispanics were generally higher than those
of other racial/ethnic populations.
• Since 2008, the rate of hepatitis A has been higher for Asians/Pacific Islanders (0.73
cases per 100,000 population in 2014) than for other race/ethnic groups.
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Figure 2.5. Availability of information on risk exposures/behaviors associated with 
hepatitis A — United States, 2014 
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*Includes case-reports indicating the presence of at least one of the following risks 2–6 weeks prior to onset of 
acute, symptomatic hepatitis A: 1) having traveled to hepatitis A-endemic regions of Mexico, South/Central 
America, Africa, Asia/South Pacific, or the Middle East; 2) having sexual/household or other contact with 
suspected/confirmed hepatitis A patient; 3) being a child/employee in day-care center/nursery/preschool or having 
had contact with such persons; 4) being involved in a foodborne/waterborne outbreak; 5) being a man who has sex 
with men; and 6) using injection drugs. 
Source: CDC, National Notifiable Diseases Surveillance System. 
 
• Of the 1,239 case-reports of hepatitis A received by CDC during 2014, a total of 506 
(41%) cases did not include a response (i.e., a “yes” or “no” response to any of the 
questions about risk exposures and behaviors) to enable assessment of risk exposures or 
behaviors. 
• Of the 733 case-reports that had risk exposure/behavior information: 
o 646 (88.1%) indicated no risk exposures/behaviors for hepatitis A and  
o 87 (11.9%) indicated at least one risk exposures/behaviors for hepatitis A during 
the 2–6 weeks prior to onset of illness.  
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Figure 2.6a. Hepatitis A reports*, by risk exposure/behavior† — United States, 2014 
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*A total of 1,239 case-reports of hepatitis A were received in 2014.
†More than one risk exposure/behavior may be indicated on each case-report.
§No risk data reported.
¶A total of 645 hepatitis A cases were reported among males in 2014.
Source: CDC, National Notifiable Diseases Surveillance System.
Figure 2.6a presents reported risk exposures/behaviors for hepatitis A during the incubation 
period, 2–6 weeks prior to onset of symptoms: 
• Of the 507 case-reports that included information about travel, 4.3% (n= 22) indicated
traveling outside of the United States or Canada.
• Of the 428 case-reports that included information about injection-drug use, 4.0% (n=17)
indicated use of injection drugs.
• Of the 44 case-reports from males that included information about sexual
preference/practices, 9.1% (n=4) indicated having sex with another man.
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Figure 2.6b. Hepatitis A reports*, by risk exposure/behavior† — United States, 2014 
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*A total of 1,239 case-reports with hepatitis A were received in 2014.
†More than one risk exposure/behavior may be indicated on each case-report.
§No risk data reported.
Source: CDC, National Notifiable Diseases Surveillance System.
Figure 2.6b presents reported risk exposures/behaviors during the incubation period, 2–6 weeks 
prior to onset of symptoms: 
• Of the 451 case-reports that contained information about contact with a hepatitis A-
infected person, 1.8% (n=8) indicated sexual or household contact with a person
confirmed or suspected of having hepatitis A.
• Of the 620 case-reports that included information about employment or attendance at a
nursery, day-care center, or preschool, 2.3% (n=14) indicated working at or attending a
nursery, day care center, or preschool.
• Of the 521 case-reports that included information about household contact with an
employee of or a child attending a nursery, day-care center, or preschool, 3.6% (n=19)
indicated such contact.
• Of the 500 case-reports that included information about linkage to an outbreak, 2.6%
(n=13) indicated exposure that may have been linked to a common-source foodborne or
waterborne outbreak.
• Of the 451 case-reports that included information about additional contact (i.e., other than
household or sexual contact) with someone confirmed or suspected of having hepatitis A,
0.4% (n=2) indicated such contact.
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Table 2.3. Number and rate* of hepatitis A-related deaths, by demographic characteristics 
and year — United States, 2010–2014 
Demographic characteristic 
2010 2011 2012 2013 2014 
No. Rate No. Rate No. Rate No. Rate No. Rate 
Age Group 
(years) 
0–34 3 0.00 0 0.00 2 0.00 2 0.00 0 0.00 
35–44 7 0.02 1 0.00 5 0.01 2 0.00 4 0.01 
45–54 25 0.06 11 0.02 12 0.03 13 0.03 7 0.02 
55–64 34 0.09 16 0.04 23 0.06 30 0.08 28 0.07 
65–74 10 0.05 12 0.05 17 0.07 19 0.08 19 0.07 
>75 16 0.09 29 0.15 18 0.09 14 0.07 18 0.09 
Race/ethnicity† 
White, NH 
(non-
Hispanic) 
65 0.03 44 0.02 51 0.02 63 0.02 51 0.02 
Black, NH 15 0.04 10 0.03 8 0.02 6 0.01 11 0.03 
Hispanic 12 0.03 6 0.02 8 0.02 8 0.02 10 0.02 
Asian/Pacific 
Islander 
2 0.02 8 0.06 7 0.05 3 0.02 2 0.01 
American 
Indian/Alaska 
Native 
1 0.05 1 0.04 2 0.08 0 0.00 2 0.10 
Sex 
Male 73 0.05 37 0.02 46 0.03 50 0.03 42 0.02 
Female 22 0.01 32 0.02 31 0.02 30 0.01 34 0.02 
Overall 95 0.03 69 0.02 77 0.02 80 0.02 76 0.02 
Source: CDC, National Vital Statistics System. 
*Rates for race, sex, and overall total are age-adjusted per 100,000 U.S. standard population in 2000. Cause of death
is defined as the underlying cause of death or one of the multiple causes of death and is based on the International
Classification of Diseases, 10th Revision (ICD-10) codes B15 (hepatitis A).
† The race category "white" Included white, non-Hispanic and white Hispanic. The race category "black" included
black, non-Hispanic and black Hispanic. The race category "non-white, non-black" included all other races.
One death in 2012 is not represented under the race/ethnicity category due to missing race and/or ethnicity data.
 In 2014, the overall hepatitis A-related mortality rate was 0.02 deaths per 100,000
population (n=76).
 From 2010–2014, the hepatitis A-related mortality rate remained steady at 0.02
deaths/100,000 population each year, except in 2010 when the mortality rate was 0.03
deaths/100,000 population.
 In 2014, age-specific mortality rates for hepatitis A increased with increasing age groups:
0.00 deaths/100,000 population among persons aged 0–34 years, 0.01 deaths/100,000
population among persons aged 35–44 years, 0.02 deaths/100,000 population among
persons aged 45-54 years, 0.07 deaths/100,000 population among persons 55–74 years,
and 0.09 deaths/100,000 population among persons aged >75 years.
 In 2014, American Indians/Alaska Natives had the highest hepatitis A-related mortality
rates at 0.1 deaths/100,000 population.
 In 2014, hepatitis A-related mortality rates were similar for both females and males (0.02
deaths/100,000 population).
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HEPATITIS B 
Acute Hepatitis B 
In 2014, a total of 2,791 cases of acute hepatitis B were reported from 48 states to CDC (Table
3.1). The overall incidence rate for 2014 was 0.9 cases per 100,000 population. After adjusting 
for under-ascertainment and under-reporting, an estimated 18,100 acute hepatitis B cases
occurred in 2014. (Data for 2014 were unavailable for the District of Columbia, Rhode Island, 
and Wyoming.) 
2012 CSTE/CDC Case Definition (NNDSS) 
Clinical Description 
Acute hepatitis is defined as acute illness with 1) discrete onset of symptoms* (e.g., fever, 
headache, malaise, anorexia, nausea, vomiting, diarrhea, and abdominal pain) and 2) jaundice or 
elevated serum alanine aminotransferase (ALT) >100 IU/L. 
Laboratory Criteria 
 Hepatitis B surface antigen (HBsAg) positive
 AND 
 Immunoglobulin M (IgM) antibody to hepatitis B core antigen (IgM anti-HBc) positive
(if done).
*A documented negative HBsAg laboratory test result within 6 months prior to a positive test
(either HBsAg, hepatitis B "e" antigen (HBeAg), or hepatitis B virus nucleic acid testing [HBV
NAT] including genotype) result does not require an acute clinical presentation to meet the
surveillance case definition.
Division of Viral Hepatitis, CDC 
25 
Table 3.1. Reported cases of acute hepatitis B, nationally and by state or jurisdiction ― 
United States, 2010–2014 
State 
2010 2011 2012 2013 2014 
No. Rate* No. Rate* No. Rate* No. Rate* No. Rate* 
Alabama 68 1.4 119 2.5 79 1.6 90 1.9 117 2.4 
Alaska 5 0.7 3 0.4 1 0.1 1 0.1 3 0.4 
Arizona 26 0.4 14 0.2 14 0.2 28 0.4 31 0.5 
Arkansas 66 2.3 57 1.9 74 2.5 50 1.7 28 0.9 
California 252 0.7 157 0.4 136 0.4 138 0.4 110 0.3 
Colorado 46 0.9 23 0.4 24 0.5 24 0.5 29 0.5 
Connecticut 22 0.6 19 0.5 15 0.4 8 0.2 9 0.3 
Delaware U U 13 1.4 11 1.2 14 1.5 8 0.9 
District of 
Columbia 3 0.5 U U U U U U U U 
Florida 297 1.6 213 1.1 247 1.3 323 1.7 313 1.6 
Georgia 165 1.7 142 1.4 109 1.1 104 1.0 103 1.0 
Hawaii 6 0.4 6 0.4 5 0.4 4 0.3 6 0.4 
Idaho 6 0.4 2 0.1 5 0.3 13 0.8 6 0.4 
Illinois 135 1.1 85 0.7 86 0.7 94 0.7 58 0.5 
Indiana 75 1.2 70 1.1 90 1.4 101 1.5 126 1.9 
Iowa 15 0.5 15 0.5 13 0.4 11 0.4 9 0.3 
Kansas 11 0.4 15 0.5 9 0.3 11 0.4 11 0.4 
Kentucky 136 3.1 151 3.5 180 4.1 214 4.9 164 3.7 
Louisiana 55 1.2 62 1.4 44 1.0 82 1.8 87 1.9 
Maine 13 1.0 8 0.6 9 0.7 11 0.8 12 0.9 
Maryland 67 1.2 62 1.1 52 0.9 43 0.7 40 0.7 
Massachusetts 13 0.2 67 1.0 75 1.1 71 1.1 30 0.4 
Michigan 122 1.2 91 0.9 81 0.8 53 0.5 50 0.5 
Minnesota 23 0.4 20 0.4 17 0.3 19 0.4 16 0.3 
Mississippi 33 1.1 57 1.9 78 2.6 55 1.8 48 1.6 
Missouri 67 1.1 60 1.0 48 0.8 61 1.0 31 0.5 
Montana 0 0.0 0 0.0 2 0.2 4 0.4 0 0.0 
Nebraska 12 0.7 12 0.7 10 0.5 9 0.5 8 0.4 
Nevada 41 1.5 29 1.1 28 1.0 29 1.0 21 0.7 
New 
Hampshire 5 0.4 3 0.2 4 0.3 2 0.2 4 0.3 
New Jersey 77 0.9 73 0.8 70 0.8 65 0.7 77 0.9 
New Mexico 5 0.2 10 0.5 3 0.1 3 0.1 2 0.1 
New York 139 0.7 134 0.7 113 0.6 117 0.6 95 0.5 
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North 
Carolina 113 1.2 109 1.1 73 0.7 75 0.8 100 1.0 
North Dakota 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
Ohio 95 0.8 90 0.8 178 1.5 225 1.9 171 1.5 
Oklahoma 115 3.1 100 2.6 79 2.1 40 1.0 57 1.5 
Oregon 42 1.1 32 0.8 25 0.6 32 0.8 32 0.8 
Pennsylvania 72 0.6 84 0.7 63 0.5 43 0.3 68 0.5 
Rhode Island U U U U U U U U U U 
South 
Carolina 59 1.3 39 0.8 37 0.8 58 1.2 37 0.8 
South Dakota 2 0.2 2 0.2 2 0.2 5 0.6 3 0.4 
Tennessee 150 2.4 192 3.0 240 3.7 262 4.0 232 3.5 
Texas 394 1.6 204 0.8 170 0.7 142 0.5 122 0.5 
Utah 8 0.3 10 0.4 13 0.5 5 0.2 11 0.4 
Vermont 2 0.3 0 0.0 2 0.3 2 0.3 4 0.6 
Virginia 97 1.2 84 1.0 84 1.0 72 0.9 61 0.7 
Washington 50 0.7 35 0.5 34 0.5 33 0.5 44 0.6 
West Virginia 88 4.7 113 6.1 141 7.6 195 10.5 186 10.1 
Wisconsin 54 0.9 17 0.3 22 0.4 9 0.2 11 0.2
Wyoming 3 0.5 0 0.0 0 0.0 U U U U 
Total 3350 1.1 2903 0.9 2895 0.9 3050 1.0 2791 0.9 
Source: CDC, National Notifiable Diseases Surveillance System. 
*Rate per 100,000 population.
†Updated data for Delaware in 2011.
U=No data available for reporting.
 The number of acute hepatitis B cases declined by 16.7%, from 3,350 in 2010 to 2,791 in
2014.  The rate of acute hepatitis cases remained essentially unchanged during 2010–
2014, ranging from 1.1 to 0.9.
 The rate of acute hepatitis B remained fairly stable from 2010 to 2014, ranging from 1.1
cases/100,000 population in 2010 to 0.9 cases/100,000 population in 2014.
 Rates of acute hepatitis B in 2014 ranged from no cases reported in Montana and North
Dakota to 10.1 cases per 100,000 population in West Virginia.
 Of the 48 states that reported acute hepatitis B cases in 2014, 32 states had rates below the
national rate of 0.9 per 100,000 population.
 The Healthy People 2020 goal (https://www.healthypeople.gov/) of reducing hepatitis B
incidence to <1.5 cases/100,000 population among adults was reached by  40 (83%)
states: Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Georgia,
Hawaii, Idaho, Illinois, Iowa, Kansas, Maine, Maryland, Massachusetts, Michigan,
Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New
Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon,
Pennsylvania, South Carolina, South Dakota, Texas, Utah, Vermont, Virginia,
Washington, and Wisconsin.
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Table 3.2. Clinical characteristics of reported cases of acute hepatitis B* ― United States, 
2014. 
Clinical characteristic† 
Availability of valid 
data† for clinical 
characteristic 
Cases with clinical 
characteristic§ 
No. % No. % 
Jaundice 2021 72.4 1544 76.4 
Hospitalized for hepatitis B 2014 72.2 1240 61.6 
Died from hepatitis B 1806 64.7 13 0.7 
Source: CDC, National Notifiable Diseases Surveillance System. 
*A total of 2,791 hepatitis B cases were reported during 2014.
†Case-reports for which questions regarding clinical characteristics were answered with “yes” or “no.” Reports with
any other response were excluded.
§Numbers and percentages represent only those case-reports for which data regarding clinical characteristics were
available; numbers likely are underestimates.
 Of the 2,791 case-reports of acute hepatitis B received in 2014, 72.4% included
information regarding whether the patient had jaundice, 72.2% included information
regarding hospitalization caused by hepatitis B, and 64.7% included information on death
from hepatitis B. (Note: more severe cases are likely to be ascertained and reported.)
 Jaundice was reported for 1,544 (76.4%) of the 2,021 acute hepatitis B case-reports that
included information about jaundice.
 Hospitalization as the result of hepatitis B was reported for 1,240 (61.6%) of the 2,014
acute hepatitis B case-reports that included information about hospitalization.
 Death from hepatitis B was reported for 13 (0.7%) of the 1,806 acute hepatitis B case-
reports that included information about death.
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Source: CDC, National Notifiable Diseases Surveillance System. 
 The number of reported cases of acute hepatitis B decreased by 65.3%, from 8,036 in
2000 to 2,791 in 2014.
 Acute hepatitis B cases have remained fairly stable from 2011-2014.
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Figure 3.1. Reported number of acute hepatitis B cases — United States, 2000–2014
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Figure 3.2. Incidence of acute hepatitis B, by age group — United States, 2000–2014 
Source: CDC, National Notifiable Diseases Surveillance System. 
 From 2003–2009, rates of acute hepatitis B declined among all age groups.
 For  age groups 30–39 and 40–49, rates of acute hepatitis B increased slightly  from 
2011–2013, and decreased slightly from 2013 to 2014.
 Rates for all other age groups decreased or stayed roughly the same among all other age 
groups from 2010–2014 .
 In 2014, rates were highest for persons aged 30–39 years (2.2 cases/100,000 population); 
the lowest rates were among children and adolescents aged <19 years (0.02
cases/100,000 population). 
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Figure 3.3. Incidence of acute hepatitis B, by sex — United States, 2000–2014 
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Source: CDC, National Notifiable Diseases Surveillance System. 
• In 2014, the rate for males was approximately 1.8 times higher than that for females (1.1 
cases and 0.6 cases per 100,000 population, respectively). 
4
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Figure 3.4. Incidence of acute hepatitis B, by race/ethnicity — United States, 2000–2014 
Source: CDC, National Notifiable Diseases Surveillance System. 
• From 2000–2014, the rate of acute hepatitis B declined among all racial and ethnic
populations.
• Acute hepatitis B rates for American Indians/Alaska Native have been unstable from
2000- 2011.  Rates increased sharply from 2001to 2002, declined from 2002 to 2004,
remained stable until another increase in 2008, declined in 2009 through 2011, and
increased 46% between 2011 and 2014.
• In 2014, the rate of acute hepatitis B was lowest among Hispanics and Asian/Pacific
Islanders (0.3 cases per 100,000 population, each) and highest for non-Hispanic whites
(0.9 cases per 100,000 population).
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Figure 3.5. Availability of information on risk exposures/behaviors associated with acute 
hepatitis B — United States, 2014 
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Source: CDC, National Notifiable Diseases Surveillance System. 
*Includes case-reports indicating the presence of at least one of the following risks 6 weeks to 6 months prior to
onset of acute, symptomatic hepatitis B: 1) using injection drugs; 2) having sexual contact with suspected/confirmed
hepatitis B patient; 3) being a man who has sex with men; 4) having multiple sex partners concurrently; 5) having
household contact with suspected/confirmed hepatitis B patient; 6) occupational exposure to blood; 7) being a
hemodialysis patient; 8) having received a blood transfusion; 9) having sustained a percutaneous injury; and 10)
having undergone surgery.
• Of the 2,791 case-reports of acute hepatitis B received by CDC during 2014, a total of
1,067 (38%) did not include a response (i.e., a “yes” or “no” response to any of the
questions about risk exposures and behaviors) to enable assessment of risk exposures or
behaviors.
• Of the 1,724 case-reports that had risk exposure/behavior information:
o 1,062 (61.6%) indicated no risk exposure/behavior for acute hepatitis B.
o 662 (38.4%) indicated at least one risk exposure/behavior for acute hepatitis B
during the 6 weeks to 6 months prior to illness onset.
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Figure 3.6a. Acute hepatitis B reports*, by risk exposure/behavior† — United States, 2014 
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Source: CDC, National Notifiable Diseases Surveillance System. 
*A total of 2,791 case-reports of acute hepatitis B were received in 2014.
†More than one risk exposure/behavior may be indicated on each case-report.
§No risk data reported.
¶A total of 1,778 acute hepatitis B cases were reported among males in 2014.
Figure 3.6a presents reported risk exposures/behaviors for hepatitis B during the incubation 
period, 6 weeks to 6 months prior to onset of symptoms.  
• Of the 1,319 case-reports that included information about injection-drug use, 25.8%
(n=340) indicated use of injection drugs.
• Of the 868 case-reports that included information about sexual contact, 3.9% (n=34)
indicated sexual contact with a person with confirmed or suspected hepatitis B.
• Of the 143 case-reports from males that included information about sexual
preference/practices, 18.2% (n=26) indicated sex with another man.
• Of the 673 case-reports that had information about number of sex partners, 28.7%
(n=193) indicated having ≥2 sex partners.
• Of the 868 case-reports that included information about household contact, 0.9% (n=8)
indicated household contact with someone with confirmed or suspected hepatitis B.
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Figure 3.6b. Acute hepatitis B reports*, by risk exposure/behavior† — United States, 2014 
Source: CDC, National Notifiable Diseases Surveillance System. 
*A total of 2,791 case-reports of hepatitis B were received in 2014.
†More than one risk exposure/behavior may be indicated on each case-report.
§Risk data not reported.
Figure 3.6b presents reported risk exposures/behaviors during the incubation period, 6 weeks to 
6 months prior to onset of symptoms.  
• Of the 1,550 case-reports that included information about occupational exposures, 0.3%
(n=5) indicated employment in a medical, dental, or other field involving contact with
human blood.
• Of the 1,126 case-reports that included information about receipt of dialysis or kidney
transplant, 0.2% (n=2) indicated patient receipt of dialysis or a kidney transplant.
• Of the 1,384 case-reports that included information about receipt of blood transfusion,
0.07% (n=1) indicated patient receipt of a blood transfusion.
• Of the 1,355 case-reports that included information about surgery, 10.8% (n=147)
indicated having surgery.
• Of the 1,277 case-reports that included information about needle-stick injury, 4.9%
(n=63) indicated having an accidental needle stick/puncture.
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Chronic Hepatitis B 
2012 CSTE/CDC Case Definition (NNDSS) 
Clinical Description 
No symptoms are required. Persons with chronic HBV infection may have no evidence of liver 
disease or may have a spectrum of disease ranging from chronic liver disease to cirrhosis or liver 
cancer.  
Laboratory Criteria 
 IgM antibodies to IgM anti-HBc negative AND a positive result on one of the following
tests: HBsAg, HBeAg, or nucleic acid test for hepatitis B virus DNA (including
qualitative, quantitative and genotype testing), OR
 HBsAg positive or nucleic acid test for HBV DNA positive (including qualitative,
quantitative and genotype testing) or HBeAg positive two times at least 6 months apart.
(Any combination of these tests performed 6 months apart is acceptable.)
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Table 3.3. Number of newly reported case-reports* of confirmed chronic hepatitis B 
submitted by states and jurisdictions, 2014 
State/Jurisdiction 
No. chronic 
hepatitis B 
case reports 
submitted † 
Alabama N§ 
Alaska N 
Arizona 98 
Arkansas N 
California 1,114 
Colorado 144 
Connecticut 72 
Delaware 88 
District of 
Columbia 
U¶ 
Florida 1,137 
Georgia N 
Hawaii 182 
Idaho 51 
Illinois 972 
Indiana U 
Iowa 66 
Kansas 116 
Kentucky N 
Louisiana 125 
Maine 44 
Maryland 498 
Massachusetts 233 
Michigan 475 
Minnesota 197 
Mississippi N 
Missouri 431 
Montana 26 
Nebraska 110 
Nevada N 
New Hampshire 28 
New Jersey 487 
New Mexico 50 
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New York State 2,255 
North Carolina 447 
North Dakota 83 
Ohio 214 
Oklahoma 86 
Oregon 97 
Pennsylvania 927 
Rhode Island U 
South Carolina 145 
South Dakota 10 
Tennessee 625 
Texas N 
Utah 34 
Vermont 34 
Virginia 341 
Washington 93 
West Virginia 218 
Wisconsin 1 
Wyoming 46 
Total 12,400 
Source: CDC, National Notifiable Diseases Surveillance System. 
*For case-definition, see https://wwwn.cdc.gov/nndss/conditions/notifiable/2016/ 
†Reports may not reflect unique cases. 
§ N= Not Reportable, past/present hepatitis C infection is not reportable in the listed state.   
¶ Cases reported by California through NNDSS were all from San Francisco County.  Differences in the number o 
cases in this table and table 3.4 is because NNSDSS and CDC’s Secure Access Management System (SAMS) have 
different deadline dated for which all annual data must be submitted. 
**U=No data available for reporting 
 
 In 2014, 40 states provided 12,400 case-reports of chronic hepatitis B. 
 Eleven states (California, Florida, Illinois, Maryland, Michigan, Missouri, New York 
State, New Jersey, North Carolina, Pennsylvania, and Tennessee) account for 75.5% of 
the chronic hepatitis B cases reported through the NNDSS in 2014. 
 New York State submitted the largest number of cases-reports (n= 2,255 or 18.2%) of 
chronic hepatitis B in 2014. 
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Table 3.4. Reported cases of chronic hepatitis B, by demographic characteristics and 
laboratory tests — Enhanced Viral Hepatitis Surveillance Sites*, 2014 
Category 
MA MI NYS† Phil SF WA Total 
No. 
 % 
No.  
% 
No. 
 % 
No.  
% 
No.  
% 
No.  
% 
No.  
%§ 
Sex 
Female 110 240 253 32 588 28 1,251 
49.1% 49.5% 42.7% 34.4% 50.5% 31.1% 47.2% 
Male 114 245 337 60 575 62 1,393 
50.9% 50.5% 56.8% 64.5% 49.4% 68.9% 52.6% 
Unknown/ 
missing 
0 0 3 1 2 0 6 
  0.0% 0.0% 0.5% 1.1% 0.2% 0.0% 0.2% 
Race/Ethnicity 
American 
Indian/ Alaska 
Native, NH 
0 3 0 0 4 0 7 
  0.0% 0.6% 0.0% 0.0% 0.3% 0.0% 0.3% 
Asian/Pacific 
Islander, NH 
66 139 209 35 603 22 1,074 
  29.5% 28.7% 35.2% 37.6% 51.8% 24.4% 40.5% 
Black,  NH 35 75 81 25 20 6 242 
15.6% 15.5% 13.7% 26.9% 1.7% 6.7% 9.1% 
White,   NH 28 149 96 5 20 11 309 
12.5% 30.7% 16.2% 5.4% 1.7% 12.2% 11.7% 
Hispanic 24 9 24 2 19 1 79 
10.7% 1.9% 4.1% 2.2% 1.6% 1.1% 3.0% 
Other,  NH 16 25 21 2 7 2 73 
7.1% 5.2% 3.5% 2.2% 0.6% 2.2% 2.8% 
Unknown/ 
missing 
  
55 
 
24.6% 
85 
 
17.5% 
162 
 
27.3% 
24 
 
25.8% 
492 
 
42.2% 
48 
 
53.3% 
866 
 
32.7% 
Age group, years 
0-14 1 8 4 3 5 0 21 
0.4% 1.6% 0.7% 3.2% 0.4% 0.0% 0.8% 
15-24 13 49 38 8 35 9 152 
5.8% 10.1% 6.4% 8.6% 3.0% 10.0% 5.7% 
25-39 94 149 205 31 373 29 881 
42.0% 30.7% 34.6% 33.3% 32.0% 32.2% 33.2% 
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40-54 68 143 195 33 422 31 892 
30.4% 29.5% 32.9% 35.5% 36.2% 34.4% 33.7% 
55+ 48 136 151 18 329 21 703 
21.4% 28.0% 25.5% 19.4% 28.2% 23.3% 26.5% 
Unknown/ 
missing 
0 0 0 0 1 0 1 
  0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 
Place of Birth 
United States 19 114 3 42 12 1 191 
8.5% 23.5% 0.5% 45.2% 1.0% 1.1% 7.2% 
Outside United 
States 
103 168 10 44 113 36 474 
46.0% 34.6% 1.7% 47.3% 9.7% 40.0% 17.9% 
Unknown/ 
missing 
102 203 580 7 1040 53 1,985 
  45.5% 41.9% 97.8% 7.5% 89.3% 58.9% 74.9% 
Hepatitis B laboratory testing¶ 
HBV surface 
antigen + 
190 326 524 65 1053 21 2,179 
84.8% 67.2% 88.4% 69.9% 90.4% 23.3% 82.2% 
[IgM anti-HBc] 
- 
71 80 111 0 0 44 306 
31.7% 16.5% 18.7% 0.0% 0.0% 48.9% 11.5% 
HBV "e" 
antigen + 
70 30 97 15 71 4 287 
31.3% 6.2% 16.4% 16.1% 6.1% 4.4% 10.8% 
HBV 
 NAT + 
155 50 268 86 999 17 1,577 
69.2% 10.3% 45.2% 92.5% 85.8% 18.9% 59.4% 
Total no. cases   224 485 593 93 1,165 90 2,650 
2014 Estimated 6,745,408 9,909,877 11,255,148 1,560,297 852,469 7,061,530 37,384,729 
population 
total** 
Rate per 
100,000 
3.3 4.9 5.3 6.0 136.7 1.3 7.1 
population 
Source: CDC, Enhanced Viral Hepatitis Surveillance Sites. 
Abbreviations: MA, Massachusetts; MI, Michigan; NYS, New York State; Phil, Philadelphia; SF, San Francisco; 
WA, Washington State 
*Chronic hepatitis B data from Florida, one of the 7 funded sites, were not included in this table.  
†New York City was not included in the case count for New York State, therefore cases and population estimates 
from New York excluded those who resided in New York City  
§The denominator used to calculate proportions was the total number of cases reported for each site. 
¶Cases can be reported with more than one laboratory test result.  
**Population estimates for the United States: http://quickfacts.census.gov/qfd/states/00000.html.  
 
 In 2014, a total of 2,650 chronic hepatitis B cases were reported by six funded sites. 
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 San Francisco reported the greatest number (n=1,165; 43.9%) and highest rate (136.7 
cases/100,000 population) of cases of chronic hepatitis B compared with the other sites. 
 Among the 2,644 cases for which sex was known, 52.6% were male. By site, the 
proportion of cases that were male ranged from 49.4% in San Francisco to 68.9% in 
Washington. 
 Among the 1,784 cases for which race/ethnicity was known, 60.2% were non-Hispanic 
Asians/Pacific Islanders. By site, the proportion of non-Hispanic Asians/Pacific Islanders 
ranged from 34.8% in Washington to 89.6% in San Francisco. 
 Most (n=1,773; 66.9%) cases of chronic hepatitis B were among persons aged 25–54 
years.  
 Among the 665 cases for which place of birth was known (n=665), those born outside of 
the United States accounted for the greatest number of chronic hepatitis B cases (n=474, 
71.3%). By site, among the cases for which place of birth was known, the proportion of 
reported chronic hepatitis B cases born outside of the United States ranged from 51.2% in 
Philadelphia to 97.3% in Washington. 
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Table 3.5. Number and rate* of hepatitis B-related deaths†, by demographic characteristics 
and year — United States, 2010–2014 
Demographic characteristic 2010 2011 2012 2013 2014 
No. Rate No. Rate No. Rate No. Rate No. Rate 
Age Group 
(years) 
0–34 48 0.03 41 0.03 38 0.03 40 0.03 35 0.02 
35–44 142 0.35 143 0.35 123 0.30 146 0.36 126 0.31 
45–54 448 1.00 421 0.94 428 0.97 389 0.89 384 0.88 
55–64 610 1.67 645 1.69 639 1.66 704 1.79 684 1.71 
65–74 296 1.36 285 1.27 314 1.31 343 1.36 358 1.36 
>75 248 1.34 269 1.42 229 1.20 251 1.29 256 1.29 
Race/ 
ethnicity§ 
White, NH 
(non-Hispanic) 
856 0.34 832 0.32 818 0.31 868 0.33 853 0.32 
Black, NH 356 0.94 373 0.98 322 0.81 384 0.98 330 0.80 
Hispanic 136 0.43 161 0.48 139 0.39 149 0.39 155 0.38 
Asian/Pacific 
Islander 
421 2.95 422 2.72 469 2.93 451 2.64 478 2.71 
American 
Indian/Alaska 
Native 
17 0.73 9 0.38 18 0.74 14 0.55 11 0.43 
Sex Male 1,316 0.81 1,321 0.80 1,272 0.75 1,375 0.79 1,307 0.74 
Female 476 0.27 483 0.26 499 0.27 498 0.26 536 0.27 
Overall 1,792 0.52 1,804 0.52 1,771 0.50 1,873 0.52 1,843 0.50 
 
*Rates for race, sex, and overall total are age-adjusted per 100,000 U.S. standard population in 2000.  
†Cause of death is defined as the underlying cause of death or one of the multiple causes of death and is based on 
the International Classification of Diseases, 10th Revision (ICD-10) codes B16, B17.0, B18.0, B18.1 (hepatitis B). 
§ Six deaths in 2010, seven deaths in 2011, five deaths in 2012, seven deaths in 2013, and 16 deaths in 2014 are not 
represented under the race/ethnicity category due to missing race and/or ethnicity data. 
Source: CDC, National Vital Statistics System. 
 
 
 In 2014, the hepatitis B-related mortality rate was 0.5 deaths/100,000 population 
(n=1,843). 
 From 2010–2014, the hepatitis B-related mortality rate remained stable at 0.5 
deaths/100,000 population. 
 In 2014, Asians/Pacific Islanders had the highest hepatitis B-related mortality rate of 2.7 
deaths/100,000 population compared to other racial/ethnic groups. Persons aged 55–64 
years had the highest age-specific mortality rate, 1.7 deaths/100,000 population. 
 In 2014, males who died with hepatitis B had a mortality rate that was nearly three times 
the mortality rate of females who died with hepatitis B (0.7 deaths/100,000 population vs. 
0.3 deaths/100,000 population). From 2010–2014, the hepatitis B-related mortality rate 
remained relatively stable for males and females. 
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HEPATITIS C 
Acute Hepatitis C 
In 2014, a total of 2,194 cases of acute hepatitis C were reported to CDC from 40 states (Table 
4.1). The overall incidence rate for 2014 was 0.7 cases per 100,000 population, an increase from 
2010–2012. After adjusting for under-ascertainment and under-reporting, an estimated 30,500 
acute hepatitis C cases occurred in 2014. (Data for 2014 were unavailable for Alaska, Arizona, 
Connecticut, Delaware, the District of Columbia, Hawaii, Iowa, Mississippi, New Hampshire, 
Rhode Island, and Wyoming.)  
2012 CSTE/CDC Case Definition (NNDSS) 
Clinical Description 
An acute illness with a discrete onset of any sign or symptom* consistent with acute viral 
hepatitis (e.g., fever, headache, malaise, anorexia, nausea, vomiting, diarrhea, and abdominal 
pain) and either a) jaundice or b) elevated serum alanine aminotransferase (ALT) levels >400 
IU/L. 
 
Laboratory Criteria 
Positive on one or more of the following three tests:  
 Antibodies to hepatitis C virus (anti-HCV) screening test with a signal-to-cutoff ratio 
predictive of a true positive as determined for the particular assay as defined by CDC. 
(URL for the signal to cut-off ratios: http://www.cdc.gov/hepatitis/HCV/LabTesting.htm) 
OR 
 Hepatitis C virus recombinant immunoblot assay (HCV RIBA) 
OR 
 Nucleic acid test (NAT) for HCV RNA (including qualitative, quantitative or genotype 
testing)  
 
AND meets the following two criteria (if additional testing is performed):  
 Absence of IgM antibody to hepatitis A virus (IgM anti-HAV) 
AND 
 Absence of IgM anti-HBc  
*A documented negative HCV antibody laboratory test result followed within 6 months by a 
positive test (as described in the laboratory criteria for diagnosis) result does not require an acute 
clinical presentation to meet the surveillance case definition. 
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Table 4.1. Reported cases of acute hepatitis C, nationally and by state and jurisdiction ― 
United States, 2010-2014 
State 
2010 2011 2012 2013 2014 
No. Rate* No. Rate* No. Rate* No. Rate* No. Rate* 
Alabama 7 0.1 23 0.5 24 0.5 30 0.6 35 0.7 
Alaska U U U U U U U U U U 
Arizona U U U U U U U U U U 
Arkansas 1 0 0 0 5 0.2 30 1.0 13 0.4 
California 32 0.1 48 0.1 63 0.2 72 0.2 73 0.2 
Colorado 20 0.4 28 0.5 42 0.8 21 0.4 33 0.6 
Connecticut 37 1.0 47 1.3 34 0.9 U U U U 
Delaware U U 3 0.3 U U U U U U 
District of 
Columbia 2 0.3 U U U U U U U U 
Florida 56 0.3 64 0.3 107 0.6 134 0.7 93 0.5 
Georgia 32 0.3 53 0.5 82 0.8 48 0.5 57 0.6 
Hawaii U U U U U U U U U U 
Idaho 11 0.7 12 0.8 11 0.7 14 0.9 6 0.4 
Illinois 1 0 6 0 26 0.2 37 0.3 27 0.2 
Indiana 27 0.4 84 1.3 110 1.7 175 2.7 122 1.8 
Iowa 0 0 0 0 3 0.1 U U U U 
Kansas 2 0.1 8 0.3 16 0.6 17 0.6 28 1.0 
Kentucky 109 2.5 142 3.2 178 4.1 226 5.1 176 4.0 
Louisiana 4 0.1 7 0.2 11 0.2 19 0.4 22 0.5 
Maine 2 0.2 12 0.9 8 0.6 8 0.6 31 2.3 
Maryland 24 0.4 35 0.6 39 0.7 53 0.9 42 0.7 
Massachusetts 13 0.2 23 0.3 37 0.6 174 2.6 228 3.4 
Michigan 45 0.5 32 0.3 76 0.8 74 0.7 78 0.8 
Minnesota 16 0.3 17 0.3 32 0.6 47 0.9 40 0.7 
Mississippi U U U U U U U U U U 
Missouri 6 0.1 8 0.1 4 0.1 6 0.1 6 0.1 
Montana 4 0.4 9 0.9 9 0.9 16 1.6 13 1.3 
Nebraska 2 0.1 2 0.1 3 0.2 2 0.1 2 0.1 
Nevada 7 0.3 10 0.4 12 0.4 9 0.3 6 0.2 
New 
Hampshire U U U U U U U U U U 
New Jersey 28 0.3 53 0.6 71 0.8 106 1.2 113 1.3 
New Mexico 14 0.7 14 0.7 21 1.0 12 0.6 16 0.8 
New York 50 0.3 52 0.3 93 0.5 131 0.7 126 0.6 
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North 
Carolina 39 0.4 60 0.6 63 0.6 79 0.8 111 1.1 
North Dakota 0 0 0 0 0 0 4 0.6 0 0 
Ohio 10 0.1 6 0.1 7 0.1 116 1.0 105 0.9 
Oklahoma 41 1.1 53 1.4 80 2.1 40 1.0 45 1.2 
Oregon 19 0.5 20 0.5 37 0.9 14 0.4 15 0.4 
Pennsylvania 26 0.2 35 0.3 66 0.5 81 0.6 69 0.5 
Rhode Island U U U U U U U U U U 
South 
Carolina 1 0 1 0 1 0 0 0 4 0.1 
South Dakota U U U U U U 1 0.1 0 0 
Tennessee 46 0.7 83 1.3 129 2 98 1.5 123 1.9 
Texas 35 0.1 37 0.1 44 0.2 28 0.1 47 0.2 
Utah 10 0.4 10 0.4 17 0.6 11 0.4 38 1.3 
Vermont 2 0.3 6 1.0 6 1.0 3 0.5 4 0.6 
Virginia 13 0.2 25 0.3 76 0.9 41 0.5 54 0.6 
Washington 25 0.4 41 0.6 54 0.8 63 0.9 82 1.2 
West Virginia 21 1.1 46 2.5 55 3.0 58 3.1 62 3.4 
Wisconsin 10 0.2 15 0.3 26 0.5 40 0.7 49 0.9 
Wyoming 0 0 2 0.4 U U U U U U 
Total  850 0.3 1232 0.4 1778 0.6 2138 0.7 2194 0.7 
Source: CDC, National Notifiable Diseases Surveillance System. 
*Rate per 100,000 population.  
U=No data available for reporting. 
 
 The number of acute cases of hepatitis C reported in the United States increased by 
44.9% from 2010 to 2011, by 44.3% from 2011 to 2012, by 20.2% from 2012 to 2013, 
and by 2.6% (2,138 cases to 2,194 cases) from 2013 to 2014.  
 The national rate of acute cases of hepatitis C has increased each year from 2010-2013, 
and remained stable at 0.7 cases per 100,000 population in 2013 and 2014. 
 Of the 40 states that submitted reports of acute hepatitis C in 2014, 20 states had rates 
below the national rate of 0.7 cases per 100,000 population.  
 Rates of acute hepatitis C ranged from no cases reported in North Dakota and South 
Dakota to 4.0 cases per 100,000 population reported in Kentucky. 
 Of the 40 reporting states, 16 —California, Florida, Georgia, Indiana, Kentucky, 
Massachusetts, Michigan, New Jersey, New York, North Carolina, Ohio, Pennsylvania, 
Tennessee, Virginia, Washington, West Virginia—accounted for over 76% of acute 
hepatitis C cases reported in 2014. 
 Of the 40 reporting states, nine (22.5%) have reached the Healthy People 2020 
(https://www.healthypeople.gov/) goal of an HCV incidence <0.25 cases/100,000 
population: California, Illinois, Missouri, Nebraska, Nevada, North Dakota, South 
Carolina, South Dakota, and Texas. 
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Table 4.2. Clinical characteristics of reported cases of acute hepatitis C* ― United States, 
2014 
Clinical characteristic 
Availability of valid 
data† for clinical 
characteristic 
Cases with clinical 
characteristic§ 
No. % No. % 
Jaundice 1,527 69.6 917 60.1 
Hospitalized for hepatitis C 1,371 62.5 733 53.5 
Died from hepatitis C 1,242 56.6 6 0.5 
Source: CDC, National Notifiable Diseases Surveillance System. 
*A total of 2,194 acute hepatitis C cases were reported during 2014. 
†Case-reports for which questions regarding clinical characteristics were answered with “yes” or “no.” 
Reports with any other response were excluded. 
§Numbers and percentages represent only those case-reports for which data regarding clinical 
characteristics were available; numbers likely are underestimates. 
 
 
 Of the 2,194 acute hepatitis C cases received during 2014, 69.6% (n=1,527) included 
information about whether the case-patient had jaundice, 62.5% (n=1,371) included 
information regarding hospitalization caused by hepatitis C, and 56.6% (n=1,242) 
included information on death from hepatitis C. (Note: more severe cases are likely to be 
ascertained and reported.) 
 Jaundice was reported for 917 (60.1%) of the 1,527 acute hepatitis C case-reports that 
included information about jaundice. 
 Hospitalization as the result of hepatitis C was reported for 733 (53.5%) of the 1,371 
acute hepatitis C case-reports that included information about hospitalization. 
 Death from hepatitis C was reported for 6 (0.5%) of the 1,242 acute hepatitis C case-
reports that included information about death.  
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Figure 4.1. Reported number of acute hepatitis C cases — United States, 2000–2014 
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Source: CDC, National Notifiable Diseases Surveillance System. 
 
 Acute hepatitis C cases declined from 2000 through 2005, and remained stable from 2005 
until 2010.  
 From 2010–2014, there was an approximate 2.6-fold increase in the number of reported 
acute hepatitis C cases from 850 to 2,194 cases, respectively.  
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Figure 4.2. Incidence of acute hepatitis C, by age group — United States, 2000–2014 
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 From 2000–2002, incidence rates for acute hepatitis C decreased among all age groups, 
except for persons aged 0–19 years; rates remained fairly constant among all age groups 
from 2002–2010. 
 From 2010 to 2014, the rate of acute hepatitis C increased among persons aged 20–29, 
30–39 and ≥60 years.  
 The largest increases were among persons aged 20–29 years (from 0.75 cases per 
100,000 population in 2010 to 2.20 cases per 100,000 population in 2014) and persons 
aged 30–39 years (from 0.60 cases per 100,000 population in 2010 to 1.66 cases per 
100,000 population in 2014).  
 In 2014, among all age groups, persons aged 20–29 years had the highest rate (2.20 cases 
per 100,000 population) and persons aged 0–19 and ≥60 years had the lowest rate (0.12 
cases per 100,000 population) of acute hepatitis C. 
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Figure 4.3. Incidence of acute hepatitis C, by sex — United States, 2000–2014 
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Source: CDC, National Notifiable Diseases Surveillance System. 
 
 Rates of acute hepatitis C decreased among males and females from 2000–2003 and 
remained fairly constant from 2004–2010. 
 From 2010–2014, rates of acute hepatitis C increased among males and females; in 2014, 
rates among males and females were 0.8 and 0.7 cases per 100,000 population, 
respectively. 
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Figure 4.4. Incidence of acute hepatitis C, by race/ethnicity — United States, 2000–2014
  
 
0.0
0.5
1.0
1.5
2.0
2.5
R
ep
o
rt
ed
 c
a
se
s/
1
0
0
,0
0
0
 p
o
p
u
la
ti
o
n
  
 
Year
American Indian/Alaska Native
Asian/Pacific Islander
Black, Non-Hispanic
White, Non-Hispanic
Hispanic
Source: CDC, National Notifiable Diseases Surveillance System. 
 
 From 2002–2010, the incidence rate of acute hepatitis C for American Indians/Alaska 
Natives remained high relative to other racial/ethnic groups. Incidence rates have since 
increased for all racial/ethnic populations. 
 From 2010–2014, acute hepatitis C rates increased among all racial/ethnic groups except 
among Asian and Pacific Islanders.  
 In 2014, rates of acute hepatitis C among American Indians/Alaska Natives; 
Asians/Pacific Islanders; Black, non-Hispanic; White, non-Hispanic; and Hispanics were 
1.32, 0.07, 0.19, 0.84, and 0.25 cases per 100,000 population, respectively. 
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Figure 4.5. Availability of information on risk exposures/behaviors associated with acute 
hepatitis C — United States, 2014 
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Source: CDC, National Notifiable Diseases Surveillance System. 
*Includes case-reports indicating the presence of at least one of the following risks 2 weeks to 6 months prior to 
onset of acute, symptomatic hepatitis C: 1) using injection drugs; 2) having sexual contact with suspected/confirmed 
hepatitis C patient; 3) being a man who has sex with men; 4) having multiple sex partners concurrently; 5) having 
household contact with suspected/confirmed hepatitis C patient; 6) having had occupational exposure to blood; 7) 
being a hemodialysis patient; 8) having received a blood transfusion; 9) having sustained a percutaneous injury; and 
10) having undergone surgery. 
 
 Of the 2,194 case-reports of acute hepatitis C received by CDC during 2014, 942 (42.9%) 
did not include a response (i.e., a “yes” or “no” response to any of the questions about 
risk exposures and behaviors) to enable assessment of risk exposures or behaviors. 
 Of 1,252 case-reports that had risk exposure/behavior information, 416 (33.2%) indicated 
no risk exposure/behavior for hepatitis C and 836 (66.8%) indicated at least one risk 
exposure/behavior in the 2 weeks to 6 months prior to illness onset. 
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Figure 4.6a. Acute hepatitis C reports*, by risk exposure/behavior† — United States, 2014 
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Source: CDC, National Notifiable Diseases Surveillance System. 
*A total of 2,194 case-reports of acute hepatitis C were received in 2014.   
† More than one risk exposure/behavior may be indicated on each case-report. 
§Risk data not reported.  
¶A total of 1,174 acute hepatitis C cases were reported among males in 2014. 
 
Figure 4.6a presents reported risk exposures/behaviors for hepatitis C during the 
incubation period, 2 weeks to 6 months prior to onset of symptoms. 
• Of the 1,030 case-reports that had information about injection drug use, 68.2% 
(n=702) indicated use of injection drugs. 
• Of the 230 case-reports from males that included information about sexual 
preferences/practices, 11.7% (n=27) indicated sex with another man.  
• Of the 35 case-reports that had information about sexual contact, 8.6% (n=3) reported 
sexual contact with a person with confirmed or suspected hepatitis C. 
• Of the 494 case-reports that had information about number of sex partners, 30.4% 
(n=150) indicated having ≥2 sex partners. 
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Figure 4.6b. Acute hepatitis C reports*, by risk exposure/behavior† — United States, 2014 
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Source: CDC, National Notifiable Diseases Surveillance System. 
*A total of 2,194 case-reports of acute hepatitis C were received in 2014.
†More than one risk exposure/behavior may be indicated on each case-report.
§Risk data not reported.
Figure 4.6b presents reported risk exposures/behaviors during the incubation period, 2 weeks to 
6 months prior to onset of symptoms. 
• Of the 887 case-reports that included information about occupational exposures, 1.0%
(n=9) indicated employment in a medical, dental, or other field involving contact with
human blood.
• Of the 811 case-reports that included information about receipt of dialysis or a kidney
transplant, 0.2% (n=2) indicated patient receipt of dialysis or a kidney transplant.
• Of the 729 case-reports that included information about surgery, 12.2% (n=89) indicated
having surgery.
• Of the 679 case-reports that included information about needle sticks, 7.7% (n=52)
indicated having an accidental needle stick/puncture.
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Hepatitis C, Past or Present 
2012 CSTE/CDC Case Definition (NNDSS) 
Clinical Description 
Most persons infected with HCV are asymptomatic; however, many have chronic liver disease, 
which can range from mild to severe. 
Laboratory Criteria 
One or more of the following three criteria (except in persons <18 months of age, for whom only 
the third criteria would satisfy the case classification):  
 Anti-HCV screening-test positive with a signal-to-cutoff ratio predictive of a true positive 
as determined for the particular assay as defined by CDC (URL for the signal-to-cutoff 
ratios: http://www.cdc.gov/hepatitis/HCV/LabTesting.htm) 
OR 
 HCV RIBA positive 
OR 
 NAT for HCV RNA positive (including qualitative, quantitative or genotype testing). 
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Table 4.3. Number of newly reported case-reports* of confirmed past or present hepatitis 
C infection submitted by states, 2014 
State/Jurisdiction 
No. past/present hepatitis 
C case-reports submitted†  
Alabama N§ 
Alaska U¶ 
Arizona U 
Arkansas N 
California** 1,317 
Colorado 3,644 
Connecticut 3,263 
Delaware U 
District of 
Columbia U 
Florida 22,253 
Georgia 4,237 
Hawaii 11 
Idaho 932 
Illinois 8,777 
Indiana U 
Iowa U 
Kansas 1,560 
Kentucky N 
Louisiana 2,116 
Maine 1,423 
Maryland 7,041 
Massachusetts 5,639 
Michigan 7,572 
Minnesota 1,899 
Mississippi N 
Missouri 6,278 
Montana 1,413 
Nebraska 926 
Nevada N 
New Hampshire N 
New Jersey 7,765 
New Mexico 2,316 
New York State 15,787 
North Carolina N 
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North Dakota 848 
Ohio 15,755 
Oklahoma 541 
Oregon 5,002 
Pennsylvania 10,395 
Rhode Island U 
South Carolina 3,586 
South Dakota 522 
Tennessee N 
Texas N 
Utah 1,492 
Vermont 902 
Virginia 5,590 
Washington 4,928 
West Virginia 6,631 
Wisconsin U 
Wyoming 502 
Total 162,863 
Source: CDC, National Notifiable Diseases Surveillance System 
*For case-definition, see http://wwwn.cdc.gov/nndss/script/ConditionList.aspx?Type=0&Yr=2012.
†Reports may not reflect unique cases.
§N=Not Reportable, past/present hepatitis C is not reportable in the listed state.
¶U= No data available for reporting
** Cases reported by California through NNDSS were all from San Francisco County.  Differences in the number o
cases in this table and table 3.4 is because NNSDSS and CDC’s Secure Access Management System (SAMS) have
different deadline dated for which all annual data must be submitted.
 In 2014, a total of 34 states notified CDC of 162,863 case-reports of past or present
hepatitis C.
 Thirteen states (Florida, Illinois, Maryland, Massachusetts, Michigan, Missouri, New
Jersey, New York State, Ohio, Oregon, Pennsylvania, Virginia, and West Virginia)
accounted for 76.4% of the past/present hepatitis C case-reports submitted through
NNDSS in 2014.
 The largest number of reports was received from Florida (n=22,253 or 13.7%).
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Table 4.4. Reported cases of past or present hepatitis C, by demographic characteristics 
and laboratory tests — Enhanced Viral Hepatitis Surveillance Sites, 2014 
Category 
FL MA MI NYS* Phil SF WA Total 
No. 
% 
No. 
% 
No. 
% 
No. 
% 
No. 
% 
No. 
% 
No. 
 % 
No. 
 %† 
Sex 
Female 
572 2,031 2,748 3,008 488 503 1,945 11,295 
54.1% 38.6% 36.5% 40.9% 35.5% 30.1% 39.9% 38.8% 
Male 
484 3,212 4,769 4,293 849 1158 2,878 17,643 
45.8% 61.0% 63.3% 58.3% 61.7% 69.2% 59.0% 60.5% 
Unknown/miss
ing 
1 20 16 58 39 12 55 201 
0.1% 0.4% 0.2% 0.8% 2.8% 0.7% 1.1% 0.7% 
 Race/ethnicity 
American 
Indian/ Alaska 
Native, NH 
2 10 62 32 1 9 0 116 
0.2% 0.2% 0.8% 0.4% 0.1% 0.5% 0.0% 0.4% 
Asian/Pacific 
Islander,  NH 
6 67 48 92 13 67 49 342 
0.6% 1.3% 0.6% 1.3% 0.9% 4.0% 1.0% 1.2% 
Black, NH 
65 171 1,457 735 217 274 115 3,034 
6.1% 3.2% 19.3% 10.0% 15.8% 16.4% 2.4% 10.4% 
White, NH 
705 1,953 3,875 3,443 196 549 1,102 11,823 
66.7% 37.1% 51.4% 46.8% 14.2% 32.8% 22.6% 40.6% 
Hispanic 
84 254 149 401 76 134 70 1,168 
7.9% 4.8% 2.0% 5.4% 5.5% 8.0% 1.4% 4.0% 
Other, 
NH 
6 127 103 111 11 21 43 422 
0.6% 2.4% 1.4% 1.5% 0.8% 1.3% 0.9% 1.4% 
Unknown/ 
missing 
189 2,681 1,839 2,545 862 619 3,499 12,234 
17.9% 50.9% 24.4% 34.6% 62.6% 37.0% 71.7% 42.0% 
Age group, years 
0-14
5 45 26 16 5 0 15 112 
0.5% 0.9% 0.3% 0.2% 0.4% 0.0% 0.3% 0.4% 
15-24
246 679 587 776 40 44 367 2,739 
23.3% 12.9% 7.8% 10.5% 2.9% 2.6% 7.5% 9.4% 
25-39
450 1,874 1,728 1,824 224 286 981 7,367 
42.6% 35.6% 22.9% 24.8% 16.3% 17.1% 20.1% 25.3% 
40-54
157 1,295 1,797 1,756 416 493 1,591 7,505 
14.9% 24.6% 23.9% 23.9% 30.2% 29.5% 32.6% 25.8% 
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199 1,370 3,395 2,969 691 832 1,924 11,380 
18.8% 26.0% 45.1% 40.3% 50.2% 49.7% 39.4% 39.1% 
Unknown/ 
missing 
0 0.0% 0 18 0 18 0 36 
0.0% 0.0% 0.0% 0.2% 0.0% 1.1% 0.0% 0.1% 
 Hepatitis C laboratory testing§ 
Anti-HCV+ 
761 3,050 5,308 5,014 644 986 1,271 17,034 
72.0% 58.0% 70.5% 68.1% 46.8% 58.9% 26.1% 58.4% 
HCV 
RNA + 
535 3,206 2,310 4,865 1,334 1,128 2,952 16,330 
50.6% 60.9% 30.7% 66.1% 96.9% 67.4% 60.5% 56.0% 
Total no. 
cases 
1,057 5,263 7,533 7,359 1,376 1,673 4,878 29,139 
2014 
Estimated 
19,893,297 6,745,408 9,909,877 11,255,148 1,560,297 852,469 5,470,019 55,686,515 
population 
total¶ 
Rate per 
100,000 5.3 78.0 76.0 65.4 88.2 196.3 89.2 52.3 
population 
Source: CDC, Enhanced Viral Hepatitis Surveillance Sites. 
Abbreviations: MA, Massachusetts; MI, Michigan; NYS, New York State; Phil, Philadelphia; SF, San Francisco; 
WA, Washington State 
*Cases and population estimates from New York excluded those who resided in New York City because New York
City was not included in the reported case counts.
†The denominator used to calculate proportions was the total number of cases reported for each site.
§Cases can be reported with more than one laboratory test result.
¶Population estimates for the United States: http://quickfacts.census.gov/qfd/states/00000.html.
 In 2014, a total of 29,139 past or present hepatitis C cases were reported by the funded
sites.
 Michigan reported more cases of past or present hepatitis C (n=7,533, 25.9%) compared
with the other sites. However, San Francisco had the highest rate of past or present
hepatitis C, with 196.3 cases per 100,000 population reported.
 Among the 29,139 cases, most (60.5%) were among males. By site, the proportion of
cases among males ranged from 45.8% in Florida to 69.2% in San Francisco.
 Among the 16,905 cases for which race/ethnicity was known, non-Hispanic Whites
accounted for the greatest proportion (69.9%) of past or present hepatitis C. By site,
among cases for which race/ethnicity was known, the proportion of non-Hispanic Whites
ranged from 38.1% in Philadelphia to 81.2% in Florida.
 Among the 29,103 cases for which age was known, 64.9% were among persons aged >40
years.
 58.4% of cases had a positive hepatitis C virus antibody test result reported. The
proportion with a positive hepatitis C virus antibody test result ranged from 26.1% in
Washington to 72.0% in Florida.
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 56.0% of cases had a positive hepatitis C RNA test result reported. The proportion with a
positive hepatitis C RNA test result ranged from 30.7% in Michigan to 96.9% in
Philadelphia
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Table 4.5. Number and rate* of hepatitis C-related deaths†, by demographic characteristic 
and year — United States, 2010-2014 
Demographic characteristic 
2010 2011 2012 2013 2014 
No. Rate No. Rate No. Rate No. Rate No. Rate 
Age 
Group 
(years)§ 
0–34 117 0.08 128 0.09 158 0.11 121 0.08 162 0.11 
35–44 712 1.73 696 1.71 622 1.54 573 1.42 552 1.36 
45–54 5,171 11.49 5,073 11.34 4,749 10.73 4,344 9.93 4,118 9.48 
55–64 7,431 20.37 8,330 21.89 9,235 23.93 9,899 25.18 9,999 24.95 
65–74 1,901 8.75 2,136 9.50 2,515 10.49 3,004 11.91 3,390 12.84 
>75 1,293 6.97 1,357 7.18 1,369 7.15 1,425 7.31 1,433 7.22 
Race/ 
ethnicity¶ 
White, NH 
(non-Hispanic) 
10,575 4.03 11,196 4.19 11,839 4.35 12,219 4.40 12,455 4.46 
Black, NH 2,981 7.72 3,167 7.89 3,232 7.81 3,520 8.35 3,540 8.12 
Hispanic 2,318 6.83 2,555 7.15 2,668 7.19 2,699 6.91 2,767 6.81 
Asian/Pacific 
Islander 
440 3.30 455 3.14 472 3.15 495 3.09 438 2.56 
American 
Indian/Alaska 
Native 
248 9.90 275 10.61 313 11.81 324 12.22 317 11.20 
Sex 
Male 11,781 6.81 12,651 7.11 13,300 7.31 13,745 7.40 13,998 7.39 
Female 4,846 2.63 5,070 2.70 5,350 2.77 5,623 2.85 5,661 2.81 
Overall 16,627 4.65 17,721 4.82 18,650 4.96 19,368 5.03 19,659 5.01 
Source: CDC, National Vital Statistics System. 
*Rates for race, sex, and overall total are age-adjusted per 100,000 U.S. standard population in 2000.
†Cause of death is defined as the underlying cause of death or one of the multiple causes of death and is based on the
International Classification of Diseases, 10th Revision (ICD-10) codes B17.1, and B18.2 (hepatitis C).
§Two deaths in 2010, one death in 2011, two deaths in 2012, two deaths in 2013, and five deaths in 2014 are not
represented under the age category due to missing age data.
¶The race/ethnicity category was added starting in 2010 to incorporate bridged race categories. 65 deaths in 2010, 73
deaths in 2011, 126 deaths in 2012, 111 deaths in 2013, and 142 deaths in 2014 are not represented under the
race/ethnicity category due to missing race and/or ethnicity data.
 Of the three types of viral hepatitis (hepatitis A, B, and C), hepatitis C accounted for the
greatest number of deaths and the highest mortality rate, at 5.0 deaths/100,000 population
in 2014.
 The overall hepatitis C-related mortality rate increased from 4.7 deaths/100,000
population in 2010 to 5.0 deaths/100,000 population in 2014.
 From 2010–2014, the age group with the highest hepatitis C-related mortality rate was
persons aged 55–64 years (25.0 deaths/100,000 population in 2014). This group
accounted for 50.9% of hepatitis C-related deaths in 2014.
 In 2014, the racial/ethnic group with the highest hepatitis C-related mortality rate was
among American Indians/Alaska Natives (11.2 deaths/100,000 population).
 From 2010–2014, the hepatitis C-related mortality rate among American Indians/Alaska
Natives increased by 13%.
 In 2014, the hepatitis C-related mortality rate for males was approximately 2.6 times the
rate for females.
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DISCUSSION 
National surveillance data for acute viral hepatitis provide essential information for identifying 
patterns and trends in viral hepatitis; providing data for national and local estimates of the health 
burden of hepatitis A, B, and C; targeting groups for whom public health intervention is needed; 
and evaluating intervention efforts. National rates for acute hepatitis A and B have been 
published since 1966, and national rates for acute hepatitis C (formerly non-A, non-B) have been 
published since 1992. Major changes in the epidemiology of these diseases have occurred since 
reporting of these infections was initiated, largely resulting from implementation of prevention 
strategies, including the introduction of effective vaccines against hepatitis A and hepatitis B. 
NNDSS, the core of viral hepatitis surveillance, was designed to enable states to notify CDC of 
infectious diseases diagnosed with a single positive laboratory test. Cases of acute and chronic 
hepatitis B and C do not fit this pattern, as additional information beyond a single laboratory test 
is required to confirm a case (35). To better count and characterize cases of viral hepatitis and 
estimate the burden of disease, CDC supplements NNDSS data with data obtained from select 
funded sites, national surveys, and vital statistics. 
Data from NNDSS reveal that from 2010 through 2014 there was a decrease of 25.8% in the 
number of reported cases of hepatitis A and an 16.7% decrease in the number of reported cases 
of acute hepatitis B; however, over that 5-year period there was a 158.1% increase in the number 
of reported cases of acute hepatitis C. Early decreases in acute hepatitis A and B reflect 
declining numbers of outbreaks reported to and known by CDC and the effects of increasing 
vaccination. The relatively stable low rates of acute hepatitis A acute hepatitis B reflect the need 
to vaccinate a portion of the population that is perhaps harder to reach.  In contrast, an 
“emerging epidemic” of acute hepatitis C has resulted from growing numbers of young, non-
urban (rural and Appalachian) white youth who have transitioned from oral prescription opioid 
abuse to injection of these opioids and heroin (15). In 2014, after adjusting for under-
ascertainment and under-reporting, the estimated number of cases of HAV, HBV, and HCV 
infections were 2,500, 19,200, and 30,500, respectively. (As noted in “Adjustments to Reported 
Cases in NNDSS,” these estimates cannot be compared directly with estimates from years prior 
to 2011, which were based on different methods of calculation.) 
Chronic hepatitis infection continues to affect millions of Americans (7, 38). In 2014, over 
12,000 reports of chronic hepatitis B and over 162,000 reports of past or current hepatitis C were 
submitted to CDC through NNDSS. Mortality data from 2014 presented in this surveillance 
report show certain socio-demographic groups to be disproportionately dying with these 
infections, specifically persons aged >55 years and American Indian/Alaska Natives (for 
hepatitis A); persons aged > 55 years of age, especially those 55-64 years of age, and 
Asians/Pacific Islanders (for hepatitis B); and persons aged 55–64 years and American 
Indians/Alaska Native (for hepatitis C).  Mortality rates in 2014 were highest among persons 
infected with HCV (5.01 deaths per 100,000 population), followed by HBV (0.50 deaths per 
100,000 population) and HAV (0.02 deaths per 100,000 population).  
CDC and state health departments rely on surveillance data to track the incidence of acute 
infection, guide development and evaluation of programs and policies designed to prevent 
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infection and minimize the public health impact of viral hepatitis, and monitor progress towards 
achieving goals established for these programs and policies. Effective systems for conducting 
surveillance for chronic HBV and HCV infections are needed to ensure accurate reporting of all 
cases and to support and evaluate prevention activities. Additional investments in surveillance at 
the local, state, and national levels are essential to build strong prevention programs that interrupt 
transmission of viral hepatitis and improve the health of those who are currently infected.  
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Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course 
Textbook. 
 Hepatitis A: http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/hepa.pdf  [PDF - 14 
Pages] 
 Hepatitis B: http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/hepb.pdf  [PDF - 24 
Pages] 
Prevention of Hepatitis A through Active or Passive Immunization: Recommendations of the 
Advisory Committee on Immunization Practices (ACIP): 
http://www.cdc.gov/mmwr/pdf/rr/rr5507.pdf  [PDF - 30 Pages] 
A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus 
Infection in the United States — Part I: Immunization of Infants, Children, and Adolescents: 
http://www.cdc.gov/mmwr/PDF/rr/rr5416.pdf  [PDF - 39 Pages] 
A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus 
Infection in the United States — Part II: Immunization of Adults: 
http://www.cdc.gov/mmwr/PDF/rr/rr5516.pdf  [PDF - 40 Pages] 
Recommendations for Identification and Public Health Management of Persons with Chronic 
Hepatitis B Virus Infection: http://www.cdc.gov/mmwr/pdf/rr/rr5708.pdf  [PDF - 28 Pages] 
Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-
Related Chronic Disease: http://www.cdc.gov/mmwr/PDF/RR/RR4719.pdf  [PDF - 54 Pages] 
2005 Guidelines for Viral Hepatitis Surveillance and Case Management: 
http://www.cdc.gov/hepatitis/PDFs/2005Guidlines-Surv-CaseMngmt.pdf   
 
